Apexigen, Inc.
(NASDAQ CM: APGN)
Rigrodsky Law, P.A. is investigating Apexigen, Inc. (“Apexigen”) regarding possible breaches of fiduciary duties and other violations of law related to Apexigen’s agreement to be acquired by Pyxis Oncology, Inc. (“Pyxis”). Under the terms of the agreement, Apexigen shareholders will receive 0.1725 shares of Pyxis per share.